Series date: 
01/01/2024 - 7:30am to 12/31/2024 - 8:03am
COURSE DIRECTOR
Shaji Kumar, M.D. and Prashant Kapoor, M.D. 

DESCRIPTION
These are weekly meetings done for the disease group members. During this meeting, we discuss patients, journal articles, and clinical trial protocols. We also develop treatment guidelines during the meeting. There are 6 meetings a month.

TARGET AUDIENCE
MD, Resident/Fellows, APP/NP, Nursing, Pharmacists, Social workers, students

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
  • Identify how to utilize the appropriate measures to risk-stratify patients with plasma cell disorders.
  • Review the best use of various testing strategies to make the right diagnosis of plasma cell disorders.
  • Define the treatment approaches that lead to the best outcomes for patients with plasma cell disorders.

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT STATEMENT(S)
AMA

The Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
 
DISCLOSURE SUMMARY
As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities.  All who are in a position to control the content are required to disclose all financial relationships with any ineligible company.   Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies:

Shaji Kumar, M.D. - Consulting - BeiGene, Calyx, CVS Caremark, Epizyme, Glycostem, IQVIA, Magenta Therapeutics, Menarini Silicon Biosystems, MSN Labs, Secure Bio Inc., Vial Health Technology Inc., Window Therapeutics Inc.

Prashant Kapoor, M.D. - Consulting - Angitia, AstaZeneca Pharmaceuticals LP, BeiGene, GlaxoSmithKline, Casma Therapeutics, Kite Pharma, Inc., Mustang Bio, Oncopeptides Inc., X4 Pharmaceuticals, Inc.
 
All relevant financial relationships have been mitigated. 

No relevant financial relationship(s) with ineligible companies:
Matthew Bass (Coordinator)
 
References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
None

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded will appear on your Transcript.
 
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

QUESTIONS?
Contact Matthew Bass
Support location: 
Minnesota

Sessions

Session Date
MAD DG Clinical Meeting: February 2, 2024 02/02/2024 - 7:30am to 8:30am
MAD DG Clinical Meeting: February 9, 2024 02/09/2024 - 7:30am to 8:30am
MAD DG Research Meeting: February 12, 2024 02/12/2024 - 12:00pm to 1:00pm
MAD DG Clinical Meeting: February 16, 2024 02/16/2024 - 7:30am to 8:30am
MAD DG Clinical Meeting: February 23, 2024 02/23/2024 - 7:30am to 8:30am
MAD DG Research Meeting: February 26, 2024 02/26/2024 - 12:00pm to 1:00pm
CANCELED: MAD DG Clinical Meeting: March 1, 2024 03/01/2024 - 7:30am to 8:30am
MAD DG Clinical Meeting March 8 2024 03/08/2024 - 7:30am to 8:30am
MAD DG Research Meeting March 11 2024 03/11/2024 - 12:00pm to 1:00pm
MAD DG Clinical Meeting March 15 2024 03/15/2024 - 7:30am to 8:30am

Pages